From molecules to medicine: a future cure for preeclampsia?Drug news & perspectives
AbstractIn the United States, preeclampsia (PreE) affects 5-7% of all pregnancies, yet represents 15% of all maternal-fetal morbidity and mortality. PreE causes fetal growth restriction, oligohydramnios, fetal death, and maternal seizures, stroke, cerebrovascular hemorrhage and death. It has immediate and potentially long-term effects on both the fetus and mother. To date, the molecular pathogenesis of PreE is largely unknown. Multiple pathways, including dysfunctional angiogenesis, inappropriate placentation, oxidative stress and an altered immunological milieu have been proposed as key players in the development of PreE. In addition, genetic factors in all of these pathways are essential components in the etiology of this disease. This review introduces the clinical presentation of PreE and its particular disease phenotype that has prompted some of the molecular investigations of its etiology. Evidence of the many molecular pathways involved in the pathogenesis of PreE, as well as the therapeutic investigations targeting these pathways, is presented.
- Antihypertensive Agents,
- Drug Design,
- Genetic Predisposition to Disease,
- Immune System,
- Oxidative Stress,
- Risk Factors,
- Signal Transduction
Published Article/Book CitationDrug news & perspectives (2009) 22:9, pp. 531-541.
Citation InformationMark Santillan, Donna A. Santillan, Curt D. Sigmund and Stephen K. Hunter. "From molecules to medicine: a future cure for preeclampsia?" Drug news & perspectives Vol. 22 Iss. 9 (2009) p. 531 - 541 ISSN: 0214-0934
Available at: http://works.bepress.com/mark_santillan/4/